Q-omics provides the consensus-scored IL7R profile across patient tissues and cancer cell-line models. IL7R expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IL7R is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IL7R RNA expression shows 21,301 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, HNSC, and LSCC as cancer lineages where IL7R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL7R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL7R survival associations across molecular data types. IL7R RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL7R RNA expression–survival associations across cancer types. High IL7R expression shows unfavorable associations in UVM and LGG, but favorable associations in LUAD, SKCM, BRCA and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for IL7R RNA expression.
This table summarizes IL7R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL7R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL7R shows lower tumor expression in LUSC, LUAD, THCA and KICH and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher IL7R RNA expression in tumor versus normal tissue (log2 FC = +1.580, t-test p < 0.001).
This table shows molecular features associated with IL7R in patient tissues and cancer cell lines. In patient samples, IL7R shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL7R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
